ArticleEndocrine, metabolic & immune disorders drug targets2026
Mechanism of Buzhong Yiqi Decoction Modulates the Wnt5a/β-catenin Signaling Pathway to Ameliorate Thyroid Inflammatory Damage in Mice with Autoimmune Thyroiditis
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Objective is to explore the mechanism by which Buzhong Yiqi decoction improves inflammatory damage in autoimmune thyroiditis (AIT) mice based on the Wnt5a/ β-catenin signaling pathway.
methodsSixty 8-week-old NOD.H-2h4 mice of SPF grade were selected and randomly divided into six groups: control group, model group, Buzhong Yiqi decoction low, middle, and high-dose groups (4.78, 9.56, 19.12 g·kg-1), and Western medicine group (selenium yeast tablets, 3.033×10-5 g·kg-1), with ten mice in each group. All groups of AIT model mice were allowed to drink a 0.05% sodium iodide solution freely for 8 weeks to establish the AIT model, while the control group drank distilled water freely. ELISA, HE staining, Real-time PCR, and Western Blot were used to assess serum antibodies, thyroid pathology, and expression levels of Wnt5a, β-catenin, PPAR, GSK-3β, IL-1β, and IL-6.
resultsThe model group showed increased TgAb and TPOAb levels (P<0.01), lymphocyte infiltration, and altered expression of Wnt5a, β-catenin, PPAR, GSK-3β, IL-1β, and IL-6 (P<0.01). Buzhong Yiqi decoction groups and Western medicine groups significantly reduced these effects, indicating improved thyroid function and inflammation reduction. DISCUSSION: Buzhong Yiqi decoction modulates the Wnt5a/β-catenin pathway, suggesting a potential therapeutic approach for AIT by reducing inflammation and restoring thyroid function.
conclusionBuzhong Yiqi decoction can effectively improve AIT inflammatory damage, and the modulation of the Wnt/β-catenin signaling pathway may be one of its intervention mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.